Insider Trading activities of Adverum Biotechnologies, Inc. (ADVM)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Adverum Biotechnologies, Inc. (ADVM) since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Adverum Biotechnologies, Inc. since year 2005. Table 2 shows the detailed insider transactions of Adverum Biotechnologies, Inc. since 2005. The reporting company's ticker symbol is ADVM. The reporting company's CIK number is 1501756.
The total value of stock buying since 2005 is $55,537,212.
The total value of stock sales since 2005 is $36,049,961.
The total value of stock option exercises since 2005 is $71,517.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Adverum Biotechnologies, Inc. (ADVM).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2019-05 20,000 $134,200 0 $0 0 $0
2015-06 0 $0 99,900 $3,904,350 14,800 $15,732
2015-05 0 $0 123,599 $4,371,389 10,500 $17,474
2015-04 0 $0 155,201 $6,144,822 39,500 $38,225
2015-01 0 $0 390,000 $21,629,400 0 $0
2014-12 0 $0 0 $0 413 $86
2014-08 2,722,702 $55,403,012 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Adverum Biotechnologies, Inc. insiders (ADVM)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2019-05-06 Scopa James Paul (Director) Buy 20,000 6.71 134,200
2015-06-15 Schwartz Steven Daniel (Director) Sale 16,875 39.86 672,671
2015-06-15 Gasmi Mehdi (SVP,Pharmaceutical Development) Sale 500 39.86 19,931
2015-06-15 Gasmi Mehdi (SVP,Pharmaceutical Development) Option Ex 500 2.75 1,375
2015-06-15 Wachter Paul (Director) Sale 1,192 39.86 47,515
2015-06-12 Hull Hans (SVP, Business Operations) Option Ex 8,300 .19 1,577
2015-06-12 Bain Linda (Chief Financial Officer) Sale 3,500 39.94 139,793
2015-06-12 Bain Linda (Chief Financial Officer) Option Ex 3,500 3.15 11,025
2015-06-11 Blumenkranz Mark S. (Director) Sale 1,900 39.97 75,939
2015-06-10 Chalberg Thomas W. (Chief Executive Officer) Sale 25,000 37.94 948,575
2015-06-10 Blumenkranz Mark S. (Director) Sale 600 39.91 23,947
2015-06-10 Guerin John Patrick Et Al (Director) Sale 699 206.00 143,994
2015-06-09 Blumenkranz Mark S. (Director) Sale 22,500 36.36 818,032
2015-06-08 Gasmi Mehdi (VP, Pharmaceutical Development) Sale 500 38.93 19,467
2015-06-08 Gasmi Mehdi (VP, Pharmaceutical Development) Option Ex 500 2.75 1,375
2015-06-08 Wachter Paul (Director) Sale 1,192 38.93 46,409
2015-06-05 Blumenkranz Mark S. (Director) Sale 5,000 40.08 200,415
2015-06-04 Hull Hans (SVP, Business Operations) Sale 2,000 37.64 75,284
2015-06-04 Hull Hans (SVP, Business Operations) Option Ex 2,000 .19 380
2015-06-01 Schwartz Steven Daniel (Director) Sale 17,250 36.46 628,917
2015-06-01 Wachter Paul (Director) Sale 1,192 36.46 43,461
2015-05-28 Gasmi Mehdi (VP, Pharmaceutical Development) Sale 500 38.02 19,009
2015-05-28 Gasmi Mehdi (VP, Pharmaceutical Development) Option Ex 500 2.75 1,375
2015-05-28 Guerin John Patrick Et Al (Director) Sale 1 208.00 208
2015-05-27 Guerin John Patrick Et Al (Director) Sale 1,205 206.00 248,230
2015-05-26 Wachter Paul (Director) Sale 1,192 37.47 44,663
2015-05-22 Schwartz Steven Daniel (Director) Sale 16,875 38.52 650,041
2015-05-21 Gasmi Mehdi (VP, Pharmaceutical Development) Sale 500 38.87 19,435
2015-05-21 Gasmi Mehdi (VP, Pharmaceutical Development) Option Ex 500 2.75 1,375
2015-05-19 Blumenkranz Mark S. (Director) Sale 3,000 36.91 110,733
2015-05-18 Wachter Paul (Director) Sale 1,192 35.31 42,085
2015-05-15 Blumenkranz Mark S. (Director) Sale 22,500 35.68 802,800
2015-05-14 Gasmi Mehdi (VP, Pharmaceutical Development) Sale 500 35.31 17,656
2015-05-14 Gasmi Mehdi (VP, Pharmaceutical Development) Option Ex 500 2.75 1,375
2015-05-13 Blumenkranz Mark S. (Director) Sale 715 34.94 24,984
2015-05-13 Bain Linda (Chief Financial Officer) Sale 285 34.94 9,958
2015-05-13 Bain Linda (Chief Financial Officer) Option Ex 285 3.15 897
2015-05-11 Blumenkranz Mark S. (Director) Sale 1,785 34.91 62,323
2015-05-11 Bain Linda (Chief Financial Officer) Sale 715 34.91 24,964
2015-05-11 Bain Linda (Chief Financial Officer) Option Ex 715 3.15 2,252
2015-05-11 Wachter Paul (Director) Sale 1,192 33.60 40,048
2015-05-08 Schwartz Steven Daniel (Director) Sale 17,250 33.05 570,095
2015-05-07 Gasmi Mehdi (VP, Pharmaceutical Development) Sale 500 33.28 16,638
2015-05-07 Gasmi Mehdi (VP, Pharmaceutical Development) Option Ex 500 2.75 1,375
2015-05-05 Chalberg Thomas W. (Chief Executive Officer) Sale 25,000 30.00 750,100
2015-05-04 Hull Hans (SVP, Business Operations) Sale 5,000 30.87 154,350
2015-05-04 Hull Hans (SVP, Business Operations) Option Ex 5,000 .19 950
2015-05-04 Bain Linda (Chief Financial Officer) Sale 2,500 31.59 78,972
2015-05-04 Bain Linda (Chief Financial Officer) Option Ex 2,500 3.15 7,875
2015-05-04 Wachter Paul (Director) Sale 1,192 30.87 36,797
2015-05-01 Blumenkranz Mark S. (Director) Sale 20,000 32.37 647,300
2015-04-28 Gasmi Mehdi (VP, Pharmaceutical Development) Sale 1,000 35.67 35,667
2015-04-28 Gasmi Mehdi (VP, Pharmaceutical Development) Option Ex 1,000 2.75 2,750
2015-04-27 Wachter Paul (Director) Sale 1,192 35.61 42,443
2015-04-23 Schwartz Steven Daniel Sale 16,875 38.62 651,661
2015-04-21 Gasmi Mehdi (VP, Pharmaceutical Development) Sale 1,000 39.21 39,211
2015-04-21 Gasmi Mehdi (VP, Pharmaceutical Development) Option Ex 1,000 2.75 2,750
2015-04-20 Wachter Paul Sale 1,192 40.19 47,910
2015-04-16 Blumenkranz Mark S. Sale 25,000 41.81 1,045,325
2015-04-14 Zygtech, Llc Sale 4,600 39.93 183,664
2015-04-14 Gasmi Mehdi (VP, Pharmaceutical Development) Sale 1,000 39.45 39,448
2015-04-14 Gasmi Mehdi (VP, Pharmaceutical Development) Option Ex 1,000 2.75 2,750
2015-04-13 Zygtech, Llc Sale 20,400 39.91 814,184
2015-04-13 Wachter Paul Sale 1,192 39.89 47,553
2015-04-09 Schwartz Steven Daniel Sale 17,250 40.05 690,828
2015-04-08 Blumenkranz Mark S. Sale 2,500 39.94 99,840
2015-04-07 Hull Hans (SVP, Business Operations) Sale 27,500 38.82 1,067,660
2015-04-07 Hull Hans (SVP, Business Operations) Option Ex 27,500 .19 5,225
2015-04-07 Gasmi Mehdi (VP, Pharmaceutical Development) Sale 9,000 38.82 349,416
2015-04-07 Gasmi Mehdi (VP, Pharmaceutical Development) Option Ex 9,000 2.75 24,750
2015-04-07 Blumenkranz Mark S. Sale 25,500 38.82 990,012
2015-01-13 Schwartz Steven Daniel Sale 91,000 55.46 5,046,860
2015-01-13 Zygtech, Llc Sale 100,000 55.46 5,546,000
2015-01-13 Chalberg Thomas W. (Chief Executive Officer) Sale 85,000 55.46 4,714,100
2015-01-13 Blumenkranz Mark S. Sale 100,000 55.46 5,546,000
2015-01-13 Wachter Paul Sale 14,000 55.46 776,440
2014-12-12 Chalberg Thomas W. (Chief Executive Officer) Option Ex 413 .21 86
2014-08-05 Koh Bong Y (10% Owner) Buy 400,000 17.00 6,800,000
2014-08-05 Vhcp Management Ii, Llc (10% Owner) Buy 400,000 17.00 6,800,000
2014-08-05 Deerfield International Master Fund, L.p. Buy 1,334,467 23.83 31,803,017
2014-08-05 Regeneron Pharmaceuticals Inc (10% Owner) Buy 588,235 17.00 9,999,995

Insider trading activities including stock purchases, stock sales, and option exercises of ADVM listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Adverum Biotechnologies, Inc. (symbol ADVM, CIK number 1501756) see the Securities and Exchange Commission (SEC) website.